OS Therapies announced meetings with FDA, MHRA, EMA, and TGA in Q2 2026 to review its Phase 3 trial design for OST-HER2, a cancer immunotherapy targeting metastatic osteosarcoma. The Phase 3 trial is set to begin in Q3 2026 in Australia and is required for accelerated approval in the US and conditional marketing in the UK and Europe. OST-HER2 has received multiple designations for rare diseases and fast track status, showing promising Phase 2b results. The company aims to obtain regulatory approvals and market access in the second half of 2026, potentially benefiting patients with limited treatment options and generating significant commercial value through a Priority Review Voucher.
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
TransUnion has enhanced its mortgage credit report by integrating TruVision™ Alternative Credit Attributes (ACA 2.0) from FactorTrust® to provide lenders with broader insights beyond traditional credit data. This new data helps lenders identify borro...
